Chiron Announces Discontinuation of SILCAAT and HBV-MF59 Trials And PA-1806 Program
EMERYVILLE, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Chiron Corporation (Nasdaq: CHIR - News) announced today decisions on three clinical development programs. Chiron is stopping SILCAAT, a Phase III study for recombinant human interleukin-2 (IL-2, aldesleukin) in patients with HIV. Chiron had expected to complete the SILCAAT trial, including final patient follow-up, in 2007. The company is reviewing data for a possible regulatory submission that may allow approval of IL-2 only in a subset of patients who do not achieve immunological response while on highly active antiretroviral therapies (HAART).
ADVERTISEMENT
In addition, the company is terminating development of PA-1806, a compound for gram negative infections in cystic fibrosis patients, and HBV-MF59, an immunotherapy for patients with chronic hepatitis B infection.
"We believe our decisions will enable Chiron to more effectively invest our resources to meet unmet medical needs and to advance our core franchises in cancer and infectious disease," said Craig Wheeler, President, Chiron BioPharmaceuticals
,[snip]. |
